Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Escherichia coli as a probiotic?

G J Jansen1, A C Wildeboer-Veloo, D van der Waaij

  • 1Laboratory of Medical Microbiology, University of Groningen, The Netherlands.

Infection
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioregulation of the digestive tract microflora.

Revue scientifique et technique (International Office of Epizootics)·2020
Same author

Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT).

The Netherlands journal of medicine·2018
Same author

Prevalence of β-lactamase-producing bacteria in human periodontitis.

Journal of periodontal research·2012
Same author

SWAB/NVALT (Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians) guidelines on the management of community-acquired pneumonia in adults.

The Netherlands journal of medicine·2012
Same author

The identification of anaerobic bacteria using MALDI-TOF MS.

Anaerobe·2011
Same author

Assessment of the microbiota of a mixed infection of the tongue using phenotypic and genotypic methods simultaneously and a review of the literature.

Anaerobe·2011

Oral treatment with Escherichia coli (E. coli) Symbio II did not alter gut microflora composition. However, it significantly boosted IgG antibody levels, indicating a specific immune response without modulating the gut microbiome.

Area of Science:

  • Immunology
  • Microbiology
  • Gastroenterology

Background:

  • The gut microbiome plays a crucial role in immune system regulation.
  • Probiotic interventions, such as oral Escherichia coli (E. coli) supplements, are explored for their potential to modulate gut microbiota and immune responses.
  • Understanding the specific effects of non-pathogenic E. coli strains on the human immune system is essential for therapeutic development.

Purpose of the Study:

  • To investigate the impact of oral non-pathogenic Escherichia coli (E. coli) (Symbioflor II) on gut microflora composition.
  • To assess the systemic humoral immune response, specifically IgG, IgA, and IgM isotypes, against E. coli cells following oral administration.
  • To determine if Symbioflor II modulates the gut microbiome or elicits a specific immune response.

Main Methods:

Related Experiment Videos

  • Ten healthy volunteers received oral E. coli (Symbioflor II) at 1x10^8 cells daily for 14 days after a 21-day pretreatment period.
  • Gut microflora composition was analyzed morphologically.
  • Systemic humoral immune response was measured using immune-fluorescence assays to quantify IgG, IgA, and IgM antibodies against E. coli.

Main Results:

  • Oral E. coli (Symbioflor II) treatment did not result in any observable changes in the morphological composition of the gut microflora.
  • Immune-fluorescence measurements showed a significant increase in circulating IgG antibodies specifically directed against the administered E. coli cells.
  • No significant changes were noted in IgA or IgM levels against the E. coli cells.

Conclusions:

  • Oral administration of non-pathogenic Escherichia coli (E. coli) (Symbioflor II) does not modulate the gut microflora in healthy individuals.
  • The treatment induces a specific systemic humoral immune response, characterized by an increase in IgG antibodies against the administered E. coli.
  • These findings suggest that Symbioflor II can elicit a targeted immune response without altering the overall gut microbial composition.